Amgen Inc (AMGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.5%. By the end of trading, Amgen fell $2.33 (-2.1%) to $106.62 on light volume. Throughout the day, 2,522,530 shares of Amgen exchanged hands as compared to its average daily volume of 3,572,900 shares. The stock ranged in price between $106.44-$109.21 after having opened the day at $109.21 as compared to the previous trading day's close of $108.95. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 33.4%, Ampio Pharmaceuticals ( AMPE), down 13.5%, Aoxing Pharmaceutical Company ( AXN), down 12.0% and Durata Therapeutics ( DRTX), down 8.2%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $82.0 billion and is part of the health care sector. Shares are up 26.9% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, IntelliPharmaCeutics International ( IPCI), up 56.0%, Biocryst Pharmaceuticals ( BCRX), up 21.5%, Bacterin International Holdings ( BONE), up 16.9% and DARA Biosciences ( DARA), up 13.0% , were all gainers within the drugs industry with Forest Laboratories ( FRX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home